Association of the COMT val158met variant with antidepressant treatment response in major depression by Baune, Bernhard et al.
Association of the COMT val158met Variant with
Antidepressant Treatment Response in Major Depression
Bernhard T Baune*,1,2, Christa Hohoff1, Klaus Berger3, Anna Neumann1, Su¨nke Mortensen1,
Tilmann Roehrs1, Ju¨rgen Deckert4, Volker Arolt1 and Katharina Domschke1
1Department of Psychiatry, University of Muenster, Muenster, Germany; 2Department of Psychiatry, James Cook University, Townsville, QLD,
Australia; 3Institute of Epidemiology and Social Medicine, University of Muenster, Muenster, Germany; 4Department of Psychiatry, University
of Wuerzburg, Wuerzburg, Germany
In several previous biochemical, pharmacological, and genetic studies, the catechol-O-methyltransferase (COMT) has been suggested to
be involved in the pathogenesis as well as the pharmacological treatment of affective disorders. In the present study, 256 patients with
major depression (DSM-IV) of Caucasian descent were genotyped for the functional COMT val158met polymorphism and characterized
for clinical response to antidepressive pharmacological treatment as measured by intra-individual changes of Hamilton Depression
(HAM-D-21) scores over 6 weeks. The COMT 158val/val genotype conferred a significant risk of worse response after 4–6 weeks of
antidepressant treatment in patients with major depression (week 4: p¼ 0.003; week 5: po0.0001; week 6: po0.0001) after Bonferroni
correction for multiple comparisons. The present results strongly point toward a negative influence of the higher activity COMT 158val/
val genotype on antidepressant treatment response during the first 6 weeks of pharmacological treatment in major depression, possibly
conferred by consecutively decreased dopamine availability. This finding suggests a potentially beneficial effect of an antidepressive add-
on therapy with substances increasing dopamine availability individually tailored according to COMT val158met genotype.
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Genetic factors have been suggested to play a pivotal role in
the individual response to antidepressant treatment. Phar-
macogenetic studies aim at identification of genetic varia-
tions that influence drug targets or factors interfering with
drug action. A number of pharmacogenetic studies have
examined association of response to antidepressants with
variation in candidate genes, particularly those involved in
the serotonergic system (eg, serotonin transporter (5-HTT),
serotonin receptor 2A (5-HT2A), monoamine oxidase A,
tryptophan hydroxylase, for review see Serretti et al, 2005).
Only few studies have focused on candidate genes
implicated in the noradrenergic or dopaminergic systems,
which, however, have been shown to have a significant
impact on the pathogenesis of depression and also to
interact with serotonergic pathways in the pharmacological
treatment of the disease. In line with the monoamine
hypothesis of depression, a deficit in brain norepinephrine
and dopamine has been demonstrated in patients with
major depression, which was reversible following pharma-
cological blockade of the norepinephrine transporter with
desipramine. However, the patients’ clinical improvement
was most significantly correlated with dopamine turnover
(Lambert et al, 2000). Accordingly, in the Flinders sensitive
line rat model of depression, decreased availability of
extracellular dopamine in the nucleus accumbens was found
to be reversible by treatment with serotonergic antidepres-
sants accompanied by improvements in depressive-like
behavior (Zangen et al, 2001; Dremencov et al, 2004).
Reciprocally, blockade of dopamine D2/D3 receptors has
been reported to acutely reverse the antidepressant effect of
selective serotonin reuptake inhibitors (SSRIs) in animal
models of depression as well as in patients suffering from
major depression (Willner, 2002; Willner et al, 2005). This is
in line with the clinical finding that augmentation of
antidepressant treatment with sustained-release bupropion,
an inhibitor of dopamine reuptake, as well as the dopamine
agonists pramipexole and ropinirole resulted in significant
reduction in the number and severity of depressive
symptoms after failure of therapy with SSRIs (Trivedi
et al, 2006; Cassano et al, 2004, 2005). Additionally,
pramipexole has been shown to ameliorate depressive
symptoms in addition to its effects on motor symptoms in
Parkinson’s disease (Barone et al, 2006).
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The catechol-O-methyltransferase (COMT) plays a pivotal
role in the degradation of norepinephrine and dopamine
(Mannisto and Kaakkola, 1999) and therefore serves as a
promising candidate in pharmacogenetic studies of anti-
depressant action. In patients with major depression,
significantly elevated erythrocyte COMT activity was
reported (Shulman et al, 1978; Davidson et al, 1979).
Accordingly, tolcapone, a COMT inhibitor, has been shown
to reverse an anhedonic state in a rat model of depression,
suggesting a potential role of tolcapone in the treatment of
depression in addition to its efficacy in Parkinson’s disease
(Moreau et al, 1994). In a clinical pilot study on the efficacy
of tolcapone in the treatment of major depressive disorder,
a significant reduction in depression severity was observed
(Fava et al, 1999).
The COMT gene (NM_000754) maps to chromosome
22q11.2, and contains a functional 472G/A single-nucleotide
polymorphism (rs4680) causing an amino-acid substitution
from valine to methionine in codon 158 (val158met) of the
membrane-bound form of the enzyme (codon 108 (val108-
met) of the soluble form). The valine allele (472G) has
initially been reported to result in a three- to fourfold higher
COMT activity as compared to the methionine allele (472A)
(Lachman et al, 1996). However, the valine allele appears
to be less expressed in the brain as compared to the
methionine allele (Bray et al, 2003; Zhu et al, 2004), which
slightly mitigates the effect to about 40% increased enzyme
activity as conferred by the valine allele (Chen et al, 2004).
The COMT val158met polymorphism has repeatedly been
investigated for association with major depression with
contradictory reports of no association (Kunugi et al, 1997;
Frisch et al, 1999; Cusin et al, 2002; Serretti et al, 2003),
possible association with the valine allele (Massat et al,
2005; Funke et al, 2005) or conversely the methionine allele
(Ohara et al, 1998). Two published studies on the role of
the COMT val158met polymorphism in antidepressant
treatment response investigating samples of 102 and 346
patients, respectively, report a tentative negative effect of
the COMT 158met/met genotype on mirtazapine and
citalopram response in major depression (Szegedi et al,
2005; Arias et al, 2006).
In the present study, the influence of the COMT
val158met polymorphism on clinical response to antide-
pressants was investigated in samples of Caucasian patients
with major depression and bipolar disorder, major depres-
sive episode, by means of a novel approach analyzing the
intra-individual rather than the averaged course of therapy
response, in an attempt to follow the recently published
American College of Neuropsychopharmacology (ACNP)
task force guidelines on response and remission in major
depressive disorder (Rush et al, 2006) and therefore to
possibly further clarify the role of COMT gene variation in
antidepressant treatment response. Since biochemical and
pharmacological studies provide support for decreased
availability of dopamine and norepinephrine as a detri-
mental factor in the pathomechanism of depression as well
as response to pharmacological antidepressive treatment,
higher COMT activity, as conferred by the COMT 158val
allele leading to decreased dopamine and norepinephrine
availability, was hypothesized to have a negative effect on
antidepressant drug response in depression. In addition,
given the inconsistent data on COMT val158met impact
on major depression published so far, we aimed at further
elucidation of the influence of the COMT val158met
polymorphism on the pathogenesis of major depression
using a categorical association study design.
MATERIALS AND METHODS
Samples
Samples of 268 unrelated Caucasian patients with a current
major depressive episode (mean age: 49.7715.4 years;
f¼ 154, m¼ 114) and 72 patients with bipolar disorder,
major depressive episode, admitted for inpatient treatment
were consecutively recruited at the Department of Psychia-
try, University of Muenster, Germany, between 2004 and
2006. For pharmacogenetic analyses, only patients with an
HAM-D admission score 410 and a treatment cycle of at
least 6 weeks from baseline were considered, leaving a
sample of N¼ 256 patients with major depression (mean
age: 50.4714.9 years; f¼ 145, m¼ 111) and 65 patients
with bipolar disorder, major depressive episode (mean age:
45.9714.5 years; f¼ 39, m¼ 26). Patients with schizoaffec-
tive disorders or comorbid substance abuse disorders,
mental retardation, neurological or neurodegenerative
disorders, impairing psychiatric evaluation were not
included in this analysis. In order to minimize the risk of
ethnic stratification, Caucasian descent was ascertained by
Caucasian background of both parents.
The control group consisted of 557 (mean age: 50.2714.2
years; f¼ 302, m¼ 255) age- and gender-matched healthy
subjects of German descent representative of the general
population, where the presence of clinically relevant
depressive symptoms was excluded using the Centre
for Epidemiological Studies Depression scale (CES-D)
(Radloff, 1977).
The ethics committee of the University of Muenster
(Muenster, Germany) approved the study. After complete
description of the study to the subjects, written informed
consent was obtained.
Assessment
Patients’ diagnoses were obtained by the use of a structured
clinical interview (SCID-I) according to the criteria of DSM-
IV (Wittchen et al, 1997), and all patients were character-
ized for family history of psychiatric disorders in first-
degree relatives. Clinical course of depression was assessed
with the Hamilton Depression (HAM-D-21) scale, the Beck’s
Depression Inventory (BDI), the Clinical Global Impression
(CGI) scale, and the Global Assessment of Functioning
(GAF) scale. While scores on the HAM-D-21 were obtained
on a weekly basis, BDI, CGI, and GAF scores were obtained
at admission and discharge only. Side effects were not
systematically assessed in detail; however, there were no
dropouts due to side effects. Age- and gender-matched
healthy controls were assessed for depressive symptoms
using the CES-D scale.
Response
Clinical response to treatment was measured by the intra-
individual changes of HAM-D-21 scores over the 6 weeks
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study period. This is in accordance with the recently
published ACNP task force guidelines on response and
remission in major depressive disorder, which recommend
monitoring of changes within a subject (for whom initial
severity is fixed) rather than comparing response rates
between subjects for whom initial values range widely (Rush
et al, 2006). The intra-individual weekly change score
introduced here considered the weekly changes in HAM-D
scores after week 1 up to week 6. The initial changes in
HAM-D occurring during week 1 were not included, as
HAM-D changes during this period were most likely not
related to antidepressant effects since antidepressants have
been regularly switched in this cohort of inpatients during
week 1. Thus, the intra-individual weekly change on the
HAM-D scale per subject was captured by calculating the
raw HAM-D score at weeks 2–6 minus HAM-D at the end of
week 1. Negative numbers of the change score (based on
raw scores) indicate a reduction on the HAM-D score
(larger numbers indicate better progress than lower
numbers) over time, whereas positive scores indicate
increase of HAM-D scores and a deterioration of mental
state over time, respectively. In additional analyses (Fig-
ure 2), a weekly percent change scores was obtained as
percent change relative to week 1. This model allows for
direct comparison of intra-individual response dynamics
over time. In addition, it corrects for improvements
unrelated to antidepressant action occurring in the first
week after admission due to the admission itself or
concomitant benzodiazepine and antipsychotic medication
with rapid onset of action.
Medication
Patients were treated in a naturalistic setting with a
variety of antidepressant medication (mirtazapine: N¼ 28
(10.9%), citalopram/escitalopram: N¼ 38 (14.8%), venlafax-
ine: N¼ 45 (17.6%), mirtazapine plus citalopram/escitalo-
pram: N¼ 38 (14.8%), mirtazapine plus venlafaxine: N¼ 63
(n¼ 24.6%), other (TCA, MAO inhibitors, lithium): N¼ 44
(17.2%)). As co-medication atypical neuroleptics (quetia-
pine, olanzapine, risperidone: N¼ 121, 47.3%) as well as
mood stabilizers (lithium, valproate acid: N¼ 60, 23.4%)
were used in addition to antidepressant treatment. Benzo-
diazepines were used in three cases only.
Genotyping
According to published protocols (Domschke et al, 2004),
fragments containing the COMT val158met polymorphism
were amplified with primers COMT-F (50-TCACCATC
GAGATCAACCCC) and COMT-R (50-ACAACGGGTCAGG
CATGCA). Standard PCR was carried out in a 20 ml volume
containing 60 ng of genomic DNA, 10 pmol of each primer,
200 mM dNTPs, 0.4 U Taqt DNA polymerase (Eppendorf
AG, Hamburg, Germany), 50 mM KCl, 2.5 mM MgCl2, and
10 mM Tris-HCl (pH 8.4). After an initial 5 min denatura-
tion at 941C, 35 cycles were carried out consisting of 30 s at
941C, 30 s at the annealing temperature of 641C, and 60 s at
721C, followed by a final extension time of 10 min at 721C in
a T-Gradient PCR System (Biometra, Goettingen, Germany).
Genotyping was performed by means of a restriction
fragment length polymorphism (RFLP) assay with the
restriction enzyme NlaIII (3 U), as recommended by
the manufacturer (New England Biolabs, Frankfurt,
Germany), resulting in 64, 18, and 13 bp bands for the
A-allele (158met) and 82 and 13 bp bands for the G-allele
(158val), respectively. A 6.7 ml portion of the digested
product was mixed with 10 ml denaturing solution and
separated for 2 h on a 15% polyacrylamide gel (ac-
rylamide : bisacrylamide¼ 37.5 : 1; Multigel-Long/Biometra,
Goettingen, Germany) containing 1TBE at 230 V/cm.
Bands were visualized by silver-staining. To minimize the
risk of genotyping errors, 60 randomized patients and 120
healthy controls were additionally genotyped by TaqMan
50-exonuclease assays using different colored fluorophores
for allele labeling and allelic discrimination by fluores-
cence signal detection (Applied Biosystems, Darmstadt,
Germany), which yielded a 100% congruence rate with
results obtained using the RFLP assay. Preparation of
PCR reaction mixtures was performed by Genesis
Workstation RSP 150 (Tecan, Crailsheim, Germany). For
PCR amplification and allelic discrimination, the ABI
Prism 7900HT Sequence Detection System and SDS soft-
ware version 2.1 (Applied Biosystems) were used. These
combined genotyping methods yielded a genotyping
completion rate of 100% for all included patients and
controls. Genotypes were determined by investigators
blinded for clinical diagnoses.
Statistical Analysis
The categorical association analysis of allele and genotype
distribution across patients with major depression
(N¼ 268) and age- and gender-matched healthy controls
(N¼ 557) was performed by means of Armitage’s trend test,
as provided by the program DeFinetti available as an online
source (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl; Sasieni, 1997).
Comparisons of HAMD, BDI, CGI, and GAF baseline
scores across genotype groups were carried out with one-
way ANOVA (42 categories) (Table 1). The pharmacoge-
netic investigation of COMT val158met genotype effects on
HAM-D change scores over 6 weeks of antidepressant
treatment was performed using an overall ANOVA with
repeated measures (genotype as fixed factor, and time point
as repeated measure; adjusted for age, gender, and family
history of psychiatric disorders) with post hoc Bonferroni
correction for multiple comparisons (Table 2).
In addition to the overall ANOVA with repeated
measures, we performed separate multiple ANOVAs with
post hoc Bonferroni test (adjusted for age, gender, and
family history of psychiatric disorders) to obtain results on
the weekly intra-individual HAM-D change scores across
genotype groups. Bonferroni correction for multiple com-
parisons (15 tests per independent variable in Table 3) set
the limit of the p-value to pp0.003. In addition, stratified
analyses for gender and family history of mental disorders
were performed as shown in Tables 2 and 3.
With these parameters, for continuous measurements,
our sample had a high power (80%) to detect a difference of
at least 2.4 points on the HAM-D scale between two
genotypes. Hardy–Weinberg equilibrium was examined
using the program Finetti provided as an online source
(http://ihg.gsf.de/cgi-bin/hw/hwa1.pl; Sasieni, 1997).
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In our sample of 268 patients and an age- and gender-
matched control sample of 557 healthy probands, no
association of the COMT val158met polymorphism with
major depression was observed (patients: val/val: 55, val/
met: 142, met/met: 71; controls: val/val: 112, val/met: 275,
met/met: 170; common odds ratio¼ 1.091, w2¼ 0.73,
p¼ 0.3916). Hardy–Weinberg equilibrium was fulfilled for
the case (p¼ 0.30) as well as the control sample (p¼ 0.97).
The pharmacogenetic sample was comprised of 256
patients with major depression (mean age: 50.4714.9;
f¼ 145, m¼ 111). The subsamples stratified for gender and
family history of mental diseases did not significantly differ
for age, education, marital status, or comorbidity with
anxiety disorders. COMT val158met genotype frequencies
in the overall pharmacogenetic sample of patients with
major depression as well as the respective subgroups
stratified for gender and family history of mental diseases
are given in Table 1. The distribution of COMT val158met
genotypes did not significantly differ from the expected
numbers calculated on the basis of observed allele
frequencies according to the Hardy–Weinberg equilibrium
(p¼ 0.53).
The mean HAM-D score at admission was 23.177.3 and
at discharge was 6.075.0, without showing any differences
between gender and family history of mental disorders.
Table 1 shows no significant differences of HAM-D, BDI,
GAF, and CGI baseline scores between COMT val158met
genotypes in the overall sample as well as stratified for
gender or family history of mental illness in first-degree
relatives.
The raw HAM-D scores over the course of 6 weeks are
presented in Figure 1, indicating only a marginal change
over time for patients with the COMT158val/val genotype
(mean change of 1.670.8; p¼ 0.13). Moreover, while
HAM-D scores significantly decreased over 6 weeks in
patients with either the val/met (mean change of 5.6 + 0.7;
po0.05) or met/met (mean change of 4.571.0; po0.05)
genotypes, after an initial slight decline, patients with the
val/val genotype showed no major change in HAM-D scores
after 3 weeks of antidepressant treatment.
Table 2 presents results of the overall ANOVA with
repeated measures (genotype as fixed factor, and time point
as repeated measure; post hoc Bonferroni correction) for the
HAM-D change scores over 6 weeks (dependent variable) of
antidepressant treatment across genotype groups stratified
for gender and family history. The COMT 158val/val
genotype as compared to the heterozygous 158val/met
genotype conferred a significant increased risk of worse
response to antidepressant treatment over 6 weeks. In
analyses stratified for gender and family history, the COMT
158val/val genotype as compared to the heterozygous
158val/met genotype showed an increased risk for worse
antidepressant treatment response after 6 weeks in men
(po0.049), women (po0.005), and subjects with a negative
(po0.005) or positive (po0.05) family history for psychia-
tric disorders in first-degree relatives (Table 2). Figure 2
demonstrates the HAM-D percent changes relative to week
1 across genotypes. While patients with the val/val genotype
hardly showed any changes on the HAM-D score over time,
the other two genotypes were related to a reduction in
HAM-D scores with pronounced effects for the val/met
genotype (Figure 2).
In Table 3, separate multivariable ANOVA analyses of the
HAM-D weekly change between weeks 1 and 6 (based on
raw scores) were performed across genotype groups,
stratified for gender and family history, and results were
adjusted for Bonferroni correction for multiple compar-
isons (significance level set to pp0.003). The COMT 158val/
val genotype as compared to the heterozygous 158val/met
genotype conferred a significant risk of worse response to
antidepressant treatment for the overall change score at
weeks 4 (po0.003), 5 (po0.0001), and 6 (po0.0001). In
addition, stratified analyses for history of psychiatric
diseases in first-degree relatives revealed a significant effect
of the COMT 158val/val genotype as compared to the
heterozygous 158val/met genotype in subjects without
family history of psychiatric disorders (po0.001) at week
5 after start of antidepressant treatment (Table 3). Similar
Table 1 COMT val158met Genotype Frequencies and Genotype
Comparisons for Clinical Characteristics at Baseline Stratified for
Gender and Family History
N¼ 256 Patients with major depression
COMT V158M genotype val/val val/met met/met p-value
Total (n) 54 133 69
HAMD baseline (mean) 22.9 23.4 22.8 40.05
BDI baseline (mean) 26.6 27.5 28.1 40.05
GAF baseline (mean) 43.7 42.1 44.1 40.05
CGI baseline (mean) 5.5 5.6 5.4 40.05
Males (n) 27 51 33
HAMD baseline (mean) 21.7 24.4 21.3 40.05
BDI baseline (mean) 24.6 29.3 26.9 40.05
GAF baseline (mean) 44.1 44.5 42.8 40.05
CGI baseline (mean) 5.4 5.7 5.3 40.05
Females (n) 27 82 36
HAMD baseline (mean) 24.2 22.7 24.2 40.05
BDI baseline (mean) 28.5 26.4 29.2 40.05
GAF baseline (mean) 43.4 42.3 43.7 40.05
CGI baseline (mean) 5.5 5.5 5.6 40.05
Family history positive (n) 20 57 35
HAMD baseline (mean) 20.3 24.2 22.5 40.05
BDI baseline (mean) 25.4 27.6 27.0 40.05
GAF baseline (mean) 47.0 42.5 44.2 40.05
CGI baseline (mean) 5.3 5.7 5.3 40.05
Family history negative (n) 34 76 34
HAMD baseline (mean) 24.5 22.7 23.2 40.05
BDI baseline (mean) 27.3 27.5 29.3 40.05
GAF baseline (mean) 42.0 41.8 43.9 40.05
CGI baseline (mean) 5.6 5.5 5.6 40.05
p-value of comparisons between genotypes by one-way ANOVA.
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results were obtained using ANOVA with repeated measures
(overall change at weeks 1–6) and separate ANOVAs
(weekly change), when a HAM-D percent change relative
to week 1 was employed (data not shown).
When investigating subgroups stratified for the type of
antidepressant medication, the negative influence of the
COMT 158val/val genotype on response was significant for
medication with mirtazapine plus venlafaxine or citalo-
pram/escitalopram (N¼ 101; po0.005), as compared to the
COMT 158val/met genotype. This effect was most promi-
nent after 4, 5, and 6 weeks of treatment (week 4: po0.019;
week 5: po0.001; week 6: po0.001). No significant COMT
val158met genotype effects on HAM-D treatment response
were found among patients receiving single antidepressants
(escitalopram, mirtazapine, venlafaxine). Exposure to aty-
pical neuroleptics or mood stabilizers was not different
between carriers of the COMT 158val and 158met alleles,
and atypical antipsychotics or mood stabilizers were not
related to treatment response after 6 weeks.
Significant effects of the COMT val158met genotype on
BDI, GAF, and CGI change scores between admission and
discharge were not observed (each measure was assessed at
baseline and discharge) (data not shown).
In the subsample of patients with bipolar disorder, major
depressive episode (N¼ 65; val/val: 12, val/met: 35, met/
met: 18), no influence of the COMT val158met variant on
HAM-D change scores could be detected (mean reduction
in HAM-D scores between weeks 1 and 6: val/val: 4.31;
val/met: 4.87; met/met: 3.91; ANOVA with repeated
measures p¼ 0.786). Furthermore, there was no signi-
ficant difference when comparing genotype frequencies
between patients with major depression and patients with
bipolar disorder, major depressive episode (w2¼ 0.12;
p¼ 0.729).
DISCUSSION
The present observations do not support a major role of the
COMT val158met variant in the pathogenesis of major
depression, confirming previous findings (Kunugi et al,
1997; Frisch et al, 1999; Cusin et al, 2002; Serretti et al,
2003).
However, applying an innovative intra-individual assess-
ment approach of response to treatment, our results suggest
a strong detrimental effect of the higher activity COMT
158val/val genotype on antidepressant treatment response
in patients with major depression, but not with bipolar
disorder. In major depressive patients homozygous for the
COMT 158val allele, increased COMT activity resulting in a
decreased availability of dopamine and norepinephrine
might impair the pharmacological efficacy of serotonergic
and noradrenergic antidepressants during the first 6 weeks
of treatment and thus be, in part, responsible for 30–40% of
patients not initially responding to antidepressant medica-
tion (Sackeim, 2001).
In the first of two previously published studies on COMT
gene influence on antidepressant response, German patients
carrying the COMT 158met/met genotype showed a slightly
slower and poorer response to treatment with mirtazapin
(N¼ 53) (Szegedi et al, 2005). Arias et al (2006) observed a
disadvantage for homozygous carriers of the COMT 158met
allele in early remission at the 6th/8th week of treatment
with citalopram in a Spanish sample of 139 patients with
Table 2 Overall Reduction in Mean HAM-D Scores Across COMT val158met Genotypes Stratified for Gender and Family History during
a 6-Week Course of Antidepressant Treatment
N¼ 256 Patients with major depression
COMT V158M val/val val/met met/met
genotype mean HAM-D reduction mean HAM-D reduction mean HAM-D reduction p-value
Total
HAM-D change scorea,b 1.6 5.6 4.5 o0.0001*
Males
HAM-D change scoresb,c 2.3 5.9 4.7 o0.049*
Females
HAM-D change scoresb,c 1.1 5.3 4.5 o0.005*
Family history positive
HAM-D change scoresb,d 1.7 5.6 4.3 o0.05*
Family history negative
HAM-D change scoresb,d 1.7 5.6 4.6 o0.005*
p-value of ANOVA with repeated measures adjusted for age, gender, and family history of psychiatric illness (aage, gender, and family history, cage and family history,
dage and gender) and with post hoc Bonferroni correction.
bMultivariable ANOVA with repeated measures for intra-individual HAM-D change scores over 6 weeks.
*Comparison of 158val/val vs 158val/met genotypes.
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major depression. These findings of a negative influence of
the 158met/met genotype appear to be in contrast with the
present observation of the 158val/val genotype conferring
higher risk of non-response. However, the presently
observed 158val/val genotype effect was most prominent
when compared to the 158val/met genotype rather than the
158met/met genotype. This might be explained in analogy
to the proposed ‘inverted U’ relationship between dopamine
levels and prefrontal function. Under this model, function
has been suggested to be optimal within a narrow range of
dopamine activity, with too little or too much dopamine
having relatively deleterious effects (Mattay et al, 2003).
Thus, both the 158met/met genotype increasing dopamine
levels as well as the 158val/val genotype impairing
dopamine availability might contribute to the risk of non-
response to antidepressant treatment, which across differ-
ent studies might be modulated by factors extrinsic to the
COMT 158val/met locus such as a specific constellation of
Table 3 Weekly Reduction of Raw HAM-D Scores Across COMT val158met Genotypes Stratified for Gender and Family History
N¼ 256 Patients with major depression
COMT V158M val/val val/met met/met
genotype mean mean Mean p-value
Total
HAMD change score at week 2a–d 0.5 3.0 2.5 0.018
HAMD change score at week 3a–d 1.2 4.1 3.2 0.024
HAMD change score at week 4a–d 2.0 5.8 5.1 0.003**
HAMD change score at week 5a–d 1.8 6.9 5.6 0.0001**
HAMD change score at week 6a–d 1.7 8.1 6.1 0.0001**
Males
HAMD change score at week 2a,b,d 0.7 2.7 2.5 0.630
HAMD change score at week 3a,b,d 1.7 4.2 3.3 0.400
HAMD change score at week 4a,b,d 2.7 6.6 5.7 0.071
HAMD change score at week 5a,b,d 2.7 7.2 5.3 0.024
HAMD change score at week 6a,b,d 3.5 9.1 6.9 0.030
Females
HAMD change score at week 2a,b,d 0.01 3.2 2.5 0.029
HAMD change score at week 3a,b,d 0.8 4.0 3.3 0.085
HAMD change score at week 4a,b,d 1.2 5.1 4.8 0.054
HAMD change score at week 5a,b,d 1.2 6.7 6.0 0.006
HAMD change score at week 6a,b,d 1.8 7.4 5.6 0.020
Family history positive
HAMD change score at week 2a–c 1.2 3.4 2.6 0.140
HAMD change score at week 3a–c 0.6 4.2 2.6 0.161
HAMD change score at week 4a–c 2.4 5.7 4.4 0.280
HAMD change score at week 5a–c 2.6 6.3 5.8 0.165
HAMD change score at week 6a–c 2.5 8.8 6.8 0.027
Family history negative
HAMD change score at week 2a–c 0.5 2.7 2.2 0.164
HAMD change score at week 3a–c 1.6 4.1 3.8 0.206
HAMD change score at week 4a–c 1.5 5.9 5.7 0.013
HAMD change score at week 5a–c 1.5 7.3 5.7 0.001**
HAMD change score at week 6a–c 2.5 7.8 5.8 0.019
aSingle multivariable ANOVA for weekly reduction of raw HAM-D change scores.
p-value of 158val/val vs 158val/met genotypes comparisons yielded from separate multivariable ANOVAs per weekly change score adjusted for ageb, genderc, family
history of psychiatric illnessd and with post hoc Bonferroni correction.
**Significant p-value for comparison of 158val/val vs 158val/met genotypes after Bonferroni correction for multiple comparisons (15 tests per independent variable sets
p-value to 0.003).
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genetic risk factors within the dopaminergic system,
differential environmental risk factors, or different sub-
clinical characteristics related to reduced or increased
dopamine tonus in the respective samples of patients with
depression (for review see Dailly et al, 2004). This notion of
dose-dependency in the dopaminergic tonus with respect to
depressive symptoms can be further illustrated by a case
report observing improved depressive symptomatology on
augmentation of antidepressant medication with bromo-
criptine 2.5–5 mg/day, whereas an increased dose of
bromocriptine 15 mg/day resulted in a deteriorated clinical
status (Wada et al, 2001). Additionally, differences in
antidepressive medication across studies may account for
the discrepant findings with regard to the associated allele.
Interestingly, stratification of patients with major depres-
sion for gender revealed that the association of the COMT
158val/val genotype with poor outcome after 5–6 weeks of
treatment was slightly more pronounced in the female
subsample. This observation is in accordance with previous
studies in obsessive–compulsive disorder, panic disorder,
and schizophrenia reporting association of the COMT
val158met polymorphism preferably in female patients
(Alsobrook et al, 2002; Domschke et al, 2004; Kremer
et al, 2003). Gender-specific effects of COMT gene variation
also fit well with findings of sexually dimorphic COMT
activity (Boudikova et al, 1990), which might be due to the
fact that estrogen can regulate COMT transcription by
binding to estrogen response elements in the promoter
region of the COMT gene (Xie et al, 1999). Thus, gender-
specific effects of the COMT val158met polymorphism
might be due to hormonal influences, gene–gene interaction
(eg, with a sex-linked gene), or gene–environment inter-
action with a gender-specific exposure possibly affecting an
intermediate phenotype common to several different
psychiatric diseases including major depression.
Our study indicates that the use of HAM-D might be more
suitable for the detection of differences in psychopathology
across COMT val158met genotypes as compared to the
subjective measure of the BDI and measures assessing
functionality (GAF and CGI), as those measures showed no
differences across COMT val158met genotypes. However,
this possible interpretation needs to be considered with
caution and warrants further clarification as the BDI, GAF,
and CGI were only measured at admission and discharge as
opposed to the weekly assessment using the HAM-D scale.
The following limitations have to be mentioned and
considered while interpreting the present results: patients
were recruited in a naturalistic setting allowing for a large
sample size, however, implying treatment with a variety of
antidepressants, no standardized dosage regime, and no
standardized control for plasma drug levels. Also, since a
priori only patients with a treatment cycle of at least 6 weeks
from baseline were included in the present study, no
dropouts due to non-response could be accounted for.
However, there were no dropouts because of side effects.
Furthermore, the sample sizes of patients with bipolar
disorder, major depressive episode, and of subgroups of
patients receiving a single antidepressive medication (as
opposed to the more frequently used combination treat-
ment) might have been too small to detect a minor genetic
effect, thus increasing the risk of a false-negative result.
Finally, although in all samples Caucasian ancestry was
ascertained by Caucasian background of both parents,
ethnic stratification even within the German population
cannot be excluded (Steffens et al, 2006), particularly since
no genomic control has been performed on the samples
presently under study.
In conclusion, the present results point toward a negative
influence of the higher activity COMT 158val/val genotype
on antidepressant treatment response during the first 6
weeks of pharmacological treatment in major depression,
possibly conferred by consecutively decreased norepinephr-
ine and dopamine availability. The latter would be in line
with a rat model of depression, where reduced dopamine
availability in response to serotonergic stimulation in the
nucleus accumbens, possibly conferred by the more active
COMT variant, has been suggested to constitute an essential
factor in the pathogenesis and course of depression as well
as a target for modulation by antidepressant drugs (Zangen
et al, 2001; Dremencov et al, 2004). Accordingly, given that
in pharmacological studies the COMT inhibitor, tolcapone,
has proven to reverse an anhedonic state in a rat model of
depression and to reduce symptom severity in the treatment
of major depression (Moreau et al, 1994; Fava et al, 1999),
Figure 1 Raw HAM-D scores between weeks 1 and 6 of antidepressant
treatment across COMT val158met genotypes in 256 subjects with major
depression.
Figure 2 Percent reduction of HAM-D scores over 6 weeks of
antidepressant treatment across COMT val158met genotypes in 256
subjects with major depression.
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the present findings support a potentially beneficial effect of
an antidepressive add-on therapy with substances increas-
ing dopamine availability individually tailored according to
COMT val158met genotype with homozygous carriers of the
COMT 158val allele potentially profiting most. Robust
identification of the COMT val158met variant as a clinical
predictor for treatment response might aid in identifying
the 30–40% of patients not responding to initial treatment
and thus provide the basis for more efficient, economical,
and time saving treatment decisions. Therefore, replication
studies preferably in large, well-characterized samples are
warranted to further clarify the role of COMT gene variation
in antidepressant treatment response.
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